Anika Therapeutics | ANIK - Current Assets


Anika Therapeutics reported $99.19M in Current Assets for its fiscal quarter ending in June of 2026.





Current Assets Change Date
Abbott USD 23.5B 1.02B Sep/2026
Agenus USD 78.81M 16.47M Jun/2026
Agios Pharmaceuticals USD 752.1M 34.43M Sep/2026
Anika Therapeutics USD 99.19M 5.63M Jun/2026
Arrowhead Research USD 1.67B 168.34M Jun/2026
Enanta Pharmaceuticals USD 198.68M 5.65M Dec/2025
Halozyme Therapeutics USD 1.85B 913.71M Sep/2026
Heron Therapeutics USD 229.84M 861K Jun/2026
Insmed USD 1.71B 72.59M Sep/2026
Integra LifeSciences USD 1.19B 1.54M Sep/2026
Intrexon USD 23.72M 45.04M Jun/2024
J&J USD 56.35B 3.42B Sep/2026
Karyopharm Therapeutics USD 126.33M 23.19M Mar/2026
Ligand Pharmaceuticals USD 608.23M 848.88M Sep/2026
MacroGenics USD 321.69M 139.16M Jun/2026
Merit Medical Systems USD 1.2B 86.58M Sep/2026
Rigel Pharmaceuticals USD 214.93M 39.53M Sep/2025
Sangamo BioSciences USD 49.89M 12.3M Jun/2025
Sanofi EUR 33.21B 1.68B Sep/2026
Smith & Nephew USD 4.39B 240M Jun/2026
Stryker USD 14.18B 235M Sep/2026
Veracyte USD 467.88M 106.9M Sep/2026
Xencor USD 498.66M 24.55M Sep/2026
Zimmer Biomet Holdings USD 5.13B 32.3M Sep/2026